AstraZeneca PLC (LON:AZN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of AstraZeneca PLC (LON:AZN) have received a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is £145.83.

Several equities analysts recently commented on AZN shares. Berenberg Bank upped their price target on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Jefferies Financial Group restated a “buy” rating and set a £150 price objective on shares of AstraZeneca in a report on Monday, November 10th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft boosted their price target on AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research report on Thursday, January 15th. Finally, Citigroup initiated coverage on AstraZeneca in a research note on Tuesday, January 27th. They set a “buy” rating and a £170 price target for the company.

AstraZeneca Trading Down 0.1%

LON AZN opened at £152.70 on Friday. The company has a market cap of £236.73 billion, a P/E ratio of 25.37, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12 month low of GBX 9,573.51 and a 12 month high of £157.32. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The company has a 50-day moving average of £140.16 and a 200-day moving average of £129.86.

Insider Transactions at AstraZeneca

In related news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total value of £40,083.12. Company insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.